Consistently, pharmacological or genetic blockade of ERK2 dimerization curtails tumor progression and metastatic traits without affecting ERK2 phosphorylation, whereas enforcing ERK2 dimerization fosters invasive phenotypes [11,12,13]. This evidence concerns the gene MAPK1 and neoplasm.